BioSpace News Archive

Peter Adams and Dave Harris at Rockies Venture Club (the oldest angel investment group in the U.S.) explored those myths and offered strategies to counter them.

Phathom announced positive results from its Phase III trial, PHALCON-EE, comparing vonoprazan against lansoprazole in patients with moderate to severe erosive esophagitis.

ChromaDex Corp. announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movement Disorders, conducted by Michèl A.A.P. Willemsen MD, PhD of Radboud University Medical Center.

Antares Pharma, Inc., a specialty pharmaceutical company, announced that it entered into an exclusive license agreement with Lipocine Inc., a clinical-stage biopharmaceutical company, for TLANDO®, an oral treatment for testosterone replacement therapy in the United States.

Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported additional biomarker data from the pediatric ACTION-Galactosemia Kids study.

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced it will host the first in a series of Key Opinion Leader (KOL) events on the emerging atopic dermatitis treatment landscape.

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the Ki-67 IHC MIB-1 pharmDx (Dako Omnis) immunohistochemistry companion diagnostic.

Bicycle Therapeutics plc today announced the closing on Friday, October 15, 2021 of its underwritten public offering of 3,726,852 American Depositary Shares (“ADSs”)

Atsena Therapeutics today unveiled its preclinical gene therapy program for X-linked retinoschisis (XLRS), a monogenic disease caused by mutations in the RS1 gene.

Isofol Medical AB,, announced that the prospectus prepared by the Company in connection with the listing on Nasdaq Stockholm has been approved and registered by the Swedish Financial Supervisory Authority.